Syncona (SYNC) H1 2025 earnings summary

Executive summary

• Net asset value (NAV) declined 5.2% to £1.14bn (178.9p/share), mainly due to quoted holdings and FX movements.

• Portfolio rebalanced toward clinical and late-stage companies, with 68.1% of value in these categories.

• Significant clinical and operational progress, including FDA approval for Autolus' AUCATZYL® (obe-cel) and key value inflection points in Beacon and Spur.

• £90m deployed in the life science portfolio; £305.6m raised across six financings, including £170.5m from external investors.

• Team expansion completed, with Kenneth Galbraith appointed as Chair of SIML.

Financial highlights

• Life science portfolio valued at £791.9m, delivering a (8.8)% return for the period.

• £25.3m in valuation uplifts from private portfolio, offset by a £75.0m decline in listed holdings and £19.5m FX loss.

• £90m deployed into the portfolio, with six financings closed and five new commitments.

• Share buyback programme expanded by £15m post-period end, with £75m allocated since September 2023 and £46.3m deployed.

• Portfolio companies raised £305.6m, with £170.5m from external investors.

Outlook and guidance

• Eight key value inflection points expected by end of CY2027, with three before end of CY2025.

• Confident in achieving £5bn NAV target by 2032, supported by robust capital pool and improving market conditions.

• Capital deployment guidance for the year remains at £150–200m.